Skip to content
Mayzent(siponimod fumarate)
Mayzent (siponimod fumarate) is a small molecule pharmaceutical. Siponimod fumarate was first approved as Mayzent on 2019-03-26. It has been approved in Europe to treat relapsing-remitting multiple sclerosis.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
immune system diseasesD007154
Trade Name
FDA
EMA
Mayzent
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Siponimod fumaric acid
Tradename
Company
Number
Date
Products
MAYZENTNovartisN-209884 RX2019-03-26
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
mayzentNew Drug Application2021-01-23
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
SIPONIMOD FUMARIC ACID, MAYZENT, NOVARTIS
2025-03-01M-274
2024-03-26NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Siponimod Fumaric Acid, Mayzent, Novartis
84924412030-11-30U-2511
79395192028-08-27DS, DP
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AA: Selective immunosuppressants
— L04AA42: Siponimod
HCPCS
No data
Clinical
Clinical Trials
40 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Condylomata acuminataD003218EFO_0007147A63.01—1114
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lamellar ichthyosisD017490Q80——1——1
Basal cell neoplasmsD018295—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471C61—3——14
Precancerous conditionsD011230—2——13
Lung neoplasmsD008175C34.90—3———3
Urinary bladder neoplasmsD001749C67—2———2
Breast neoplasmsD001943EFO_0003869C5011———2
Multiple sclerosisD009103EFO_0003885G3511———2
Tobacco use disorderD014029F17—2———2
HypercholesterolemiaD006937HP_0003124—1———1
VulvodyniaD056650N94.81—1———1
DyspareuniaD004414HP_0030016N94.1—1———1
Show 11 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Head and neck neoplasmsD0062581————1
Non-small-cell lung carcinomaD0022891————1
Hiv infectionsD015658EFO_0000764B201————1
Barrett esophagusD001471EFO_0000280K22.71————1
NeoplasmsD009369C801————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Human influenzaD007251EFO_0007328J11.1————22
ObesityD009765EFO_0001073E66.9————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSIPONIMOD FUMARATE
INNsiponimod
Description
Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS). It is intended for once-daily oral administration.
Classification
Small molecule
Drug classimmunomodulators
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1.CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1.O=C(O)/C=C/C(=O)O
Identifiers
PDB—
CAS-ID1230487-00-9
RxCUI—
ChEMBL IDCHEMBL4298150
ChEBI ID—
PubChem CID44599207
DrugBankDB12371
UNII IDRR6P8L282I (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Mayzent - Novartis
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,053 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
37 adverse events reported
View more details